argenx (ENXTBR:ARGX): Assessing Valuation Ahead of Antibody Engineering & Therapeutics Conference Updates
argenx (ENXTBR:ARGX) heads into the Antibody Engineering and Therapeutics conference in San Diego, with investors watching closely for fresh signals on its antibody pipeline and what that might mean for the stock.
See our latest analysis for argenx.
The conference buzz comes after a strong run for argenx, with the share price now at $753.2 and a roughly 18% 3 month share price return contributing to a 106% three year total shareholder return. This suggests momentum is still very much on its side.
If argenx has you thinking more broadly about biotech opportunities, this could be a good moment to explore other innovative names across healthcare stocks for fresh ideas.
With the shares already near analyst targets yet still screening as significantly undervalued on some intrinsic measures, the key question now is whether argenx is a rare bargain in biotech or if the market is already pricing in years of growth.
Most Popular Narrative Narrative: 1.7% Undervalued
With argenx last closing at $753.2 against a narrative fair value of $766.06, expectations are finely balanced ahead of fresh pipeline updates.
The analysts have a consensus price target of €712.238 for argenx based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €885.0, and the most bearish reporting a price target of just €480.0.
Curious how rapid revenue growth, shifting margins and a lower future earnings multiple can still point to upside from here? Unpack the full valuation blueprint.
Result: Fair Value of $766.06 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, a tougher competitive landscape and heavier rebate pressures could quickly erode Vyvgart’s pricing power and compress margins, which would challenge today’s upbeat valuation narrative.
Find out about the key risks to this argenx narrative.
Build Your Own argenx Narrative
If you see the story differently or want to investigate the numbers yourself, you can build a personalised view in just minutes: Do it your way.
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding argenx.
Looking for more investment ideas?
Before you move on, consider using targeted screeners on Simply Wall St to help identify your next round of opportunities so strong candidates do not slip past your watchlist.
- Explore potential turnaround stories by reviewing under the radar companies that appear cheap on a cash flow basis through these 908 undervalued stocks based on cash flows.
- Focus on cutting edge innovation by targeting companies that use algorithms and automation in healthcare via these 30 healthcare AI stocks.
- Respond to market volatility by examining listed companies involved in blockchain adoption and digital assets using these 80 cryptocurrency and blockchain stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com